Stocks · News reference

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Jul 30, 2026, 9:49 AMBenzinga Newsdesk

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 30, 2026, 9:49 AM
Checked: Jul 30, 2026, 9:49 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 4, 2026, 12:12 PMBenzinga Newsdesk
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
Read original at benzinga
ADPT
BenzingaJul 30, 2026, 5:21 PMBenzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22
Read original at benzinga
ADPT
BenzingaJul 30, 2026, 3:34 PMBenzinga Newsdesk
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28
Read original at benzinga
ADPT
BenzingaJul 30, 2026, 1:48 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25
Read original at benzinga
ADPT